| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 162 | 2022 |
| Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis E Curtit, V Nerich, L Mansi, L Chaigneau, L Cals, C Villanueva, F Bazan, ... The oncologist 18 (6), 667-674, 2013 | 120 | 2013 |
| Interaction between phytotherapy and oral anticancer agents: prospective study and literature review AL Clairet, M Boiteux-Jurain, E Curtit, M Jeannin, B Gérard, V Nerich, ... Medical Oncology 36, 1-18, 2019 | 62 | 2019 |
| Rapalogs efficacy relies on the modulation of antitumor T-cell immunity L Beziaud, L Mansi, P Ravel, EL Marie-Joseph, C Laheurte, L Rangan, ... Cancer Research 76 (14), 4100-4112, 2016 | 59 | 2016 |
| Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. E Curtit, A Thiery-Vuillemin, T Nguyen, B Heyd, X Pivot, V Di Martino, ... Journal of clinical oncology: official journal of the American Society of …, 2011 | 54 | 2011 |
| A randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects X Pivot, E Curtit, YJ Lee, G Golor, A Gauliard, D Shin, Y Kim, H Kim, ... Clinical Therapeutics 38 (7), 1665-1673. e3, 2016 | 42 | 2016 |
| Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay E Curtit, L Mansi, Y Maisonnette-Escot, JL Sautière, X Pivot European Journal of Surgical Oncology (EJSO) 43 (5), 921-930, 2017 | 29 | 2017 |
| Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer A Thiery-Vuillemin, E Curtit, T Maurina, D Montange, C Succi, T Nguyen, ... Annals of oncology 23 (11), 2992-2993, 2012 | 28 | 2012 |
| Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer F Calcagno, T Nguyen, E Dobi, C Villanueva, E Curtit, S Kim, ... Clinical Medicine Insights: Oncology 7, CMO. S7256, 2013 | 22 | 2013 |
| Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma … S Kim, E Dobi, M Jary, F Monnien, E Curtit, T NGuyen, Z Lakkis, B Heyd, ... BMC cancer 13, 1-10, 2013 | 21 | 2013 |
| Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature L Garnier, F Ducray, C Verlut, MI Mihai, F Cattin, A Petit, E Curtit Frontiers in Oncology 9, 177, 2019 | 18 | 2019 |
| Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer F Bazan, E Dobi, B Royer, E Curtit, L Mansi, N Menneveau, MJ Paillard, ... BMC cancer 19, 1-6, 2019 | 16 | 2019 |
| Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice E Curtit, JM Vannetzel, JC Darmon, S Roche, H Bourgeois, S Dewas, ... The Breast 44, 39-45, 2019 | 16 | 2019 |
| GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients DG Cox, E Curtit, G Romieu, P Fumoleau, M Rios, H Bonnefoi, T Bachelot, ... Oncotarget 7 (47), 77358, 2016 | 16 | 2016 |
| Targeting the RAS signalling pathway in cancer L Mansi, E Viel, E Curtit, J Medioni, C Le Tourneau Bulletin Du Cancer 98 (9), 1019-1028, 2011 | 16 | 2011 |
| Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis A Thiery-Vuillemin, D Montange, E Kalbacher, T Maurina, T Nguyen, ... Annals of oncology 22 (9), 2152-2154, 2011 | 16 | 2011 |
| First description of a sporadic breast cancer in a woman with BRCA1 germline mutation E Curtit, V Benhamo, N Gruel, T Popova, E Manie, P Cottu, O Mariani, ... Oncotarget 6 (34), 35616, 2015 | 15 | 2015 |
| Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines E Curtit, P Nouyrigat, N Dohollou, E Levy, A Lortholary, J Gligorov, ... European Journal of Cancer 47 (16), 2396-2402, 2011 | 15 | 2011 |
| Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to … V Mueller, A Wardley, E Paplomata, E Hamilton, A Zelnak, ... European Journal of Cancer 153, 223-233, 2021 | 14 | 2021 |
| Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice G Mouillet, A Falcoz, J Fritzsch, H Almotlak, P Jacoulet, X Pivot, ... Quality of Life Research, 1-12, 2021 | 13 | 2021 |
